[go: up one dir, main page]

MX9301214A - 1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene. - Google Patents

1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene.

Info

Publication number
MX9301214A
MX9301214A MX9301214A MX9301214A MX9301214A MX 9301214 A MX9301214 A MX 9301214A MX 9301214 A MX9301214 A MX 9301214A MX 9301214 A MX9301214 A MX 9301214A MX 9301214 A MX9301214 A MX 9301214A
Authority
MX
Mexico
Prior art keywords
alcoxi
pct
cycloalkyloxy
preparation
benzene
Prior art date
Application number
MX9301214A
Other languages
English (en)
Inventor
Andrew James Ratcliffe
Garry Fenton
Jonathan Stephen Mason
Malcom Norman Palfreyman
Original Assignee
Rhone Poulenc Rorer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd
Publication of MX9301214A publication Critical patent/MX9301214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
    • C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a compuestos de 1-alcoxi-2-(alcoxi- o cicloalquiloxi)-4-(ciclotioalquilo ciclotialquenil)benceno, que inhiben la AMP fosfodiesterasa cíclica o el factor de necrosis del tumor (TNF, por sus siglas en inglés) y que son útiles en tratar pacientes que sufren de un estado de enfermedad capaz de ser modulado, al inhibir la producción de la AMP fosfodiesterasa cíclica o del TNF, mediante la administración del compuesto al paciente. La invención también se refiere a la preparación de estos compuestos, a las composiciones farmacéuticas que contienen estos compuestos y a los métodos para su uso farmacéutico.
MX9301214A 1992-03-04 1993-03-04 1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene. MX9301214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929204808A GB9204808D0 (en) 1992-03-04 1992-03-04 Novel compositions of matter

Publications (1)

Publication Number Publication Date
MX9301214A true MX9301214A (es) 1994-03-31

Family

ID=10711570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301214A MX9301214A (es) 1992-03-04 1993-03-04 1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene.

Country Status (12)

Country Link
US (1) US5541219A (es)
EP (1) EP0629197B1 (es)
JP (1) JPH07504201A (es)
AT (1) ATE157092T1 (es)
AU (1) AU3640793A (es)
CA (1) CA2130938A1 (es)
DE (1) DE69313267T2 (es)
GB (1) GB9204808D0 (es)
IL (1) IL104959A0 (es)
MX (1) MX9301214A (es)
WO (1) WO1993018024A1 (es)
ZA (1) ZA931560B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311282D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
IL117090A (en) * 1995-02-10 2000-07-26 Schering Ag Pharmaceutical compositions containing oxazolidinone derivatives
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
EP1140895B1 (en) * 1999-01-07 2004-03-24 Fujisawa Pharmaceutical Co., Ltd. Thiopyran compounds as inhibitors of mmp
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
HK1047276A1 (zh) * 1999-10-25 2003-02-14 Altana Pharma Ag 作为pde4抑制剂的四氢噻喃2，3-二氮杂萘酮类衍生物
DE19954569A1 (de) * 1999-11-12 2001-05-17 Schwabe Willmar Gmbh & Co Pharmakologisch aktive Tetrahydrothiopyran-4-ol-Derivate, Verfahren zu ihrer Herstellung und Verwendung
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR102034748B1 (ko) 2011-03-01 2019-10-21 시너지 파마슈티컬즈 인코포레이티드 구아닐레이트 사이클라제 c 작용제의 제조 방법
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794026A (en) * 1955-04-11 1957-05-28 Dow Chemical Co Thiapyrylium and thiophenium compounds
US3558641A (en) * 1967-10-06 1971-01-26 Merck & Co Inc Certain pyridyl salicylic acid derivatives
US3657432A (en) * 1969-06-25 1972-04-18 Merck & Co Inc Anti-inflammatory salicylic acid derivatives
FR2187308B1 (es) * 1972-06-01 1975-08-08 Roussel Uclaf
US3832354A (en) * 1972-08-01 1974-08-27 Sandoz Ltd 4-hydroxy-5-phenyl-3-thiophene acetic acids and their derivatives
US4198519A (en) * 1976-07-30 1980-04-15 Beecham Group Limited Anti-inflammatory compounds
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US5149828A (en) * 1987-09-30 1992-09-22 Ciba-Geigy Ag Stabilizers for color photography recording materials
US4778819A (en) * 1988-01-27 1988-10-18 Uniroyal Chemical Company, Inc. 2-(tetrahydro-2-thienyl)phenols and carbamate derivatives thereof
US5030647A (en) * 1990-02-09 1991-07-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-inflammatory thienylbenzylamine compounds
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5358938A (en) * 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase

Also Published As

Publication number Publication date
JPH07504201A (ja) 1995-05-11
ZA931560B (en) 1994-05-11
US5541219A (en) 1996-07-30
IL104959A0 (en) 1993-07-08
CA2130938A1 (en) 1993-09-16
EP0629197B1 (en) 1997-08-20
GB9204808D0 (en) 1992-04-15
ATE157092T1 (de) 1997-09-15
EP0629197A1 (en) 1994-12-21
AU3640793A (en) 1993-10-05
WO1993018024A1 (en) 1993-09-16
DE69313267T2 (de) 1998-02-26
DE69313267D1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
MX9301214A (es) 1-alcoxi-2-(alcoxi-o cicloalquiloxi)-4-(ciclotioalquil o ciclotioalquenil-)benceno, proceso para su preparacion y composicion farmaceutica que lo co ntiene.
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
PT652868E (pt) Inibidores da fosfodiesterase do amp ciclico
NO972261D0 (no) Hypolipidemiske benzodiazepiner
UA41297C2 (uk) Похідні індолу, фармацевтична композиція і спосіб лікування
PT73879B (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
GB9202791D0 (en) Compounds
ATE206123T1 (de) Phenylxanthin-derivate
KR870700599A (ko) 카르복실산유도체, 그의 제조방법, 이화합물을 함유한 약제조성물 및 그의 용도
FR2721608B1 (fr) Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DK0696283T3 (da) 2-, 3,- 4,- 5,- 6,- 7,- 8,- 9,- og/eller 10 substituerede dibenzoxazepinforbindelser, lægemidler og anvendelser
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
ATE190484T1 (de) Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen
FR2700165B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
RU94040719A (ru) 2,3,4,5-тетрагидро-1h-3-бензазепины, фармацевтическая композиция, способ лечения и способ получения
DE59004597D1 (de) Alkandiyl-bis-carbonamide, Adhäsivkomponenten zur Behandlung kollagenhaltiger Materialien zur Anwendung in der Medizin, enthaltend diese Verbindungen.
ATE306260T1 (de) Monomere der 4,4-(disubstituierten)cyclohexan-1- ole und verwandte verbindungen
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen
RU95104980A (ru) Производные бензола, способы их получения, фармацевтические композиции, содержащие их и способы лечения
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
MX9704740A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados.